Abstract:
The cost of health care is continuing to escalate world wide. More people are living longer and often with more challenging medical conditions. The personal and societal cost for survival is growing yearly.
Medical and surgical advances, unfortunately, have not been able to stop this growing financial burden. Occasionally new surgical interventions can favorably affect the overall health care cost. If an intervention can create a healthier patient with fewer health care needs, society may experience an overall saving. Such was the early hope for Lung Volume Reduction Surgery (LVRS).
If LVRS can save productive lives and reduce a patients’ ongoing need for medicines, such as oxygen therapy, there may be an overall financial gain to society. If, however, LVRS differs costs into the future as well as add the new surgical costs clearly there will be no overall saving. In this later instance the gain to a patients’ well being must be weighed against the cost of the intervention. Lastly when there is no overall gain for the patient and no saving to society it is clear that we should not invest in the intervention.
This chapter reviews the tools used to evaluate a patients health-related quality of life (HRQOL) and reviews the world literature evaluating health gains and losses following LVRS. The cost of LVRS to society will be reviewed and compared with other medical and surgical interventions with an emphasis on other treatments for advanced emphysema.
We begin with a general outline of the definition of Quality of Life (QOL), and a review of the research tools in use to evaluate QOL. These tools can be designed to assess a patients’ quality of life specifically as it related to a particular disease state such as chronic obstructive lung disease (COPD) (a disease specific QOL measure), or it can be designed as a broader tool assessing QOL as ones’ general health impacts on their perception of well being.
The two major short-comings of a QOL measure is its subjective nature (individual preference based) and its inability to include one of the worst health related outcomes, death. Traditionally a subject who has died is not able to report on their QOL and is omitted from further assessment and is not included in the group assessment. Only patients who are able to complete the questionnaire at the give time are included in that time’s overall group score. Health Utilities, however, is a societal preference based score and ascribes the value zero for death. It therefore can be used as a tool to follow a group of patients over time and include loss of life in the overall scoring of health quality for that group.
Healthcare economists can use health utility (HU) scores of a study group over time as a measure of that groups’ overall health for that time period. It is reported in units called Quality Adjusted Life Years (QALYs). A comparison between research groups allows the investigator an opportunity to assess the gain or loss of health. This difference is also reported in quality adjusted life years (QALYs). Knowing the gain or loss in QALYs and the cost difference between two groups allows the economist to report the cost per QALY. The cost per QALY is a value of a very general nature and allows for comparison of interventions of various types to one and other.
This chapter will outline in more detail each of these measures and tools and discuss their application to the financial assessment of LVRS.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- COPD:
-
chronic obstructive pulmonary disease
- CRDQ:
-
Chronic Respiratory Disease Questionnaire
- CUA:
-
cost utility assessment
- CUI:
-
cost utility index
- DLCO:
-
Carbon monoxide diffusion capacity
- FEV1:
-
forced expiratory volume in one second
- HRQOL:
-
health-related quality of life
- HUI:
- ICER:
-
The incremental cost-utility ratio
- ISOLDE:
-
inhaled steroid in obstructive lung disease
- LTOT:
-
long-term oxygen therapy
- LVRS:
-
lung volume reduction surgery
- MICD:
-
minimal important clinical difference
- MRC:
-
Modified Medical Research Council Dyspnea Index
- NETT:
-
National Emphysema Treatment Trial
- NHP:
-
Nottingham Health Profile
- Pao2:
-
peripheral arterial oxygen content
- PFSDQ:
-
Pulmonary Function Status and Dyspnea Questionnaire
- PFSS:
-
pulmonary function status scale
- PR:
- QALYs:
-
quality adjusted life years
- QOL:
-
quality of life
- QWB:
-
Quality of Well-Being Questionnaire
- SF-36:
-
Short Form 36 questionnaire
- SGRQ:
-
St. George’s Respiratory Questionnaire
- SIP:
-
sickness impact profile
- SOLQ:
-
Seattle Obstructive Lung Disease Questionnaire
References
Aaron S, Vandemheen M, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O’Donnell D,McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins H, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M. (2007). Ann Intern Med. 146: 545–555.
Anderson KL. (1999). Am J Crit Care. 8: 389–396.
Appleton S, Adams R, Porter S, Peacock M, Ruffin R. (2003). Chest. 123: 1838–1846.
Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MM, Cates CJ. (2006). Cochrane Database Syst Rev. Issue 3. Art. No: CD001104.
Bergner M, Bobbitt RA, Carter WB. (1981). Med Care. 19: 787–805.
Bergner M, Bobbitt RA, Pollard WE. (1976). Med Care. 14: 57–67.
Brenner M, McKenna RJ, Gelb AF. (1997). Chest. 112: 916–923.
Brusasco V, Hodder R, Miravitlles M. (2003). Thorax. 58: 399–404.
Burge PS, Calverley PM, Jones PW. (2000). BMJ. 320: 1297–1303.
Cambach W, Wagenaar RC, Koelman TW. (1999). Arch Phys Med Rehabil. 80: 103–111.
Ciccone AM, Meyers BF, Guthrie TJ. (2003). J Thorac Cardiovasc Surg 125: 513–525.
Cooper JD, Trulock EP, Triantafillou AN. (1995). J Thorac Cardiovasc Surg. 109: 106–116.
Dahl R, Grerst LA, Nowak D. (2001). Am J Respir Crit Care Med. 164: 778–784.
Domingo-Salvany A, Lamarca R, Ferrer M. (2002). Am J Respir Crit Care. Med 166: 680–685.
Donohue JF, van Noord JA, Bateman ED. (2002). Chest. 122: 47–55.
Eaton T, Garrett JE, Young P, Fergusson W, Kolbe J, Rudkin S, Whyte K. (2002). Eur Respir J. 20: 306–312.
Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE. (2003). N Engl J Med. 348: 2059–2073.
Flanagan JC. (1978). Am Psychol. 33: 138–147.
Geddes D, Davies M, Koyama H. (2000). N Engl J Med. 343: 239–245.
Goldstein RS, Todd TRJ, Guyett G. (2003). Thorax. 58: 405–410.
Guyatt GH, Berman LB, Townsend M. (1987). Thorax. 42: 773–778.
Hamacher J, Buchi S, Georgescu CL. (2002). Eur Respir J. 19: 54–60.
Hillerdal G, Lofdahl CG, Strom K, Skoogh BE, Jorfeldt L, Nilsson F. (2005). Chest. 128: 3489–3499.
Hutton J, Brown R, Borowitz M. (1996). Pharmacoeconomics. 9(Suppl 2): 8–22.
Hunt SM, McEwen J, McKenna SP. (1985). J R Coll Gen Pract. 35: 185–188.
Jones PW, Quirk FH, Baveystock CM. (1992). Am Rev Respir Dis. 145: 1321–1327.
Kaplan RM, Ries AL. (2005). J Cardiopulm Rehabil. 25: 321–331.
Lacasse Y, Goldstein R, Lasserson TJ, Martin S. (2006) Cochrane Database Syst Rev. Issue 4. Art. No.: CD003793.
Lareau SC, Carrieri-Kohlman V, Janson-Bjerklie S. (1994). Heart Lung. 23: 242–250.
Lofdahl CG, Hillerdal G, Strom K. (2000). Am J Respir Crit Care Med. 161: A585.
Miller JD, Malthaner RA, Goldsmith CH, Goeree R, Higgins D, Cox PG, Tan L, Road JD. (2006). Ann Thorac Surg 2006 81: 314–321.
Moy ML, Ingenito EP, Mentzer SJ, Evans RB, Reilly JJ Jr. (1999). Chest 115: 383–389.
Na JO, Kim DS, Yoon SH. (2005). Monaldi Arch Chest Dis. 63: 30–36
Nannini L, Cates CJ, Lasserson TJ, Poole P. (2007a). Cochrane Database Syst Rev. Issue 4. Art. No.: CD003794.
Nannini LJ, Cates CJ, Lasserson TJ, Poole P. (2007b). Cochrane Database Syst Rev. Issue 4. Art. No.: CD006826.
Nannini LJ, Cates CJ, Lasserson TJ, Poole P. (2007c). Cochrane Database Syst Rev. Issue 4. Art. No.: CD006829.
Naunheim K, Wood D, Fishman A. (2006). Ann Thorac Surg. 82: 431–443.
Nonoyama ML, Brooks D, Lacasse Y, Guyatt GH, Goldstein RS. (2007). Cochrane Database Syst Rev. Issue 4. Art. No.: CD005372.
O’Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk D, Balter M, Ford G, Gervais A, Goldstein R, Hodder R, Maltais F, Road J. (2003). Can Respir J. 10(Suppl): 11A–65A.
Okubadejo AA, Paul EA, Jones PW, Wedzicha JA. (1996). Eur Respir J. 9: 2335–2339.
Pompeo E, Marino M, Notroni I, Matteucci G, Mineo TC. (2003). Ann Thorac Surg. 70: 948–954.
Ramsey S, Shroyer L, Sullivan S, Wood D. (2007). Chest. 131: 823–832.
Tanni SE, Vale SA, Lopes PS, Guiotoko MM, Godoy IL, Godoy IR. (2007). J Bras Pneumol. 33: 161–167.
Testa MA, Simonson DC. (1996). N Engl J Med. 334: 835–840.
Tiong LU, Davies HRHR, Gibson PG, Hensley MJ, Hepworth R, Lasserson TJ, Smith B. (2006). Cochrane Database Syst Rev. Issue 4. Art. No.: CD001001.
Tu S, McDonell M, Spertus J. (1997). Chest. 112: 614–622.
Ware JE Jr, Sherbourne CD. (1992). Med Care. 30: 473–483.
Yang IA, Fong KM, Sim EHA, Black PN, Lasserson TJ. (2007). Cochrane Database Syst Rev. Issue 4. Art. No.: CD002991.
Yusen RD, Morrow LE, Brown KL. (2002). Semin Thorac Cardiovasc Surg. 14: 403–412.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media LLC
About this entry
Cite this entry
Miller, J.D., Altaf, F. (2010). Quality of Life and Financial Measures in Surgical and Non-Surgical Treatments in Emphysema. In: Preedy, V.R., Watson, R.R. (eds) Handbook of Disease Burdens and Quality of Life Measures. Springer, New York, NY. https://doi.org/10.1007/978-0-387-78665-0_137
Download citation
DOI: https://doi.org/10.1007/978-0-387-78665-0_137
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-78664-3
Online ISBN: 978-0-387-78665-0
eBook Packages: MedicineReference Module Medicine